Educational Videos

Estimated time to complete activity: 1 hour 30 minutes

Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES

Understand the evolving landscape of inflammation, including newly identified molecular pathways, and review how targeting such new targets has improved patient outcomes over the past decade

• Discuss the shift toward stratifying inflammatory diseases by immune pathways, identified via biomarkers, and by patterns of tissue involvement, rather than clinical phenotype alone

• Explore future directions in inflammatory therapeutics, including early intervention, emerging targets, and the potential role of biosimilars, generics, and novel therapies in reshaping treatment approaches

TARGET AUDIENCE

This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory diseases.

PROGRAMME OVERVIEW

This webinar examines evolving molecular pathways, the shift toward biomarker-driven disease stratification, and how emerging therapies — including biosimilars, generics, and novel targets — are transforming patient outcomes and clinical practice.

DISCLOSURE OF CONFLICTS OF INTEREST

CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.